Read by QxMD icon Read


Salvatore Annunziata, Annarosa Cuccaro, Maria Chiara Tisi, Stefan Hohaus, Vittoria Rufini
AIM: To retrospectively investigate the prognostic role of the ratio between target lesion and liver SUVmax (rPET) in patients with follicular lymphoma (FL) submitted to FDG-PET/CT at the end of immuno-chemotherapy (PI-PET), and to compare rPET with International Harmonization Project criteria (IHP), Deauville Score (5p-DS) and FL International Prognostic Index at diagnosis (FLIPI). METHODS: Eighty-nine patients with FL undergoing PI-PET were evaluated. The receiver operating characteristic (ROC) approach was applied to identify the optimal cut-point of rPET with respect to 5-years progression free survival (PFS)...
February 20, 2018: Annals of Nuclear Medicine
Andrea Gallamini, Corrado Tarella, Simonetta Viviani, Andrea Rossi, Caterina Patti, Antonino Mulé, Marco Picardi, Alessandra Romano, Maria Cantonetti, Giorgio La Nasa, Livio Trentin, Silvia Bolis, Davide Rapezzi, Roberta Battistini, Daniela Gottardi, Paolo Gavarotti, Paolo Corradini, Michele Cimminiello, Corrado Schiavotto, Guido Parvis, Roberta Zanotti, Guido Gini, Andrés J M Ferreri, Piera Viero, Maurizio Miglino, Atto Billio, Abraham Avigdor, Alberto Biggi, Federico Fallanca, Umberto Ficola, Michele Gregianin, Agostino Chiaravalloti, Giuseppe Prosperini, Fabrizio Bergesio, Stephane Chauvie, Chiara Pavoni, Alessandro Massimo Gianni, Alessandro Rambaldi
Purpose To investigate the progression-free survival (PFS) of patients with advanced Hodgkin lymphoma (HL) after a risk-adapted treatment strategy that was based on a positive positron emission tomography scan performed after two doxorubicin, vinblastine, vincristine, and dacarbazine (ABVD) cycles (PET2). Patients and Methods Patients with advanced-stage (IIB to IVB) HL were consecutively enrolled. After two ABVD cycles, PET2 was performed and centrally reviewed according to the Deauville five-point scale. Patients with a positive PET2 were randomly assigned to four cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) followed by four cycles of standard BEACOPP with or without rituximab...
January 23, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Zhitao Ying, Lan Mi, Xuejuan Wang, Yuewei Zhang, Zhi Yang, Yuqin Song, Xiaopei Wang, Wen Zheng, Ningjing Lin, Meifeng Tu, Yan Xie, Lingyan Ping, Chen Zhang, Weiping Liu, Lijuan Deng, Jun Zhu
Objective: High-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) is the standard of care in the upfront or relapsed/refractory setting in some patients with non-Hodgkin lymphoma (NHL). However, a proportion of patients do not respond to ASCT. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) has been widely used for staging, response evaluation, and prognosis prediction. Here, we investigated the prognostic role of PET/CT in NHL patients before and after ASCT...
December 2017: Chinese Journal of Cancer Research, Chung-kuo Yen Cheng Yen Chiu
Thibault Salomon, Catherine Nganoa, Anne-Claire Gac, Christophe Fruchart, Gandhi Damaj, Nicolas Aide, Charline Lasnon
AIM: Our aim was (1) to evaluate the prevalence of steatosis in lymphoma patients and its evolution during treatment; (2) to evaluate the impact of hepatic steatosis on18 F-FDG liver uptake; and (3) to study how hepatic steatosis affects the Deauville score (DS) for discriminating between responders and non-responders. METHODS: Over a 1-year period, 358 PET scans from 227 patients [122 diffuse large B cell lymphoma (DLBCL), 57 Hodgkin lymphoma (HL) and 48 Follicular lymphoma (FL)] referred for baseline (n = 143), interim (n = 79) and end-of-treatment (EoT, n = 136) PET scans were reviewed...
December 26, 2017: European Journal of Nuclear Medicine and Molecular Imaging
Hugo J A Adams, John M H de Klerk, Josien C Regelink, Ben G F Heggelman, Stefan V Dubois, Thomas C Kwee
A 22-year-old woman was diagnosed with intermediate risk stage II Hodgkin lymphoma and treated with three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by involved-field radiation therapy. A complete metabolic remission was achieved after two cycles of ABVD, which was maintained until three years after completion of treatment. Follow-up FDG-PET/CT four years after completion of treatment, however, showed a new FDG-avid (Deauville score of 4) lesion in the right scapula, suggesting relapsed disease...
December 2017: Nuclear Medicine and Molecular Imaging
Blandine Enilorac, Charline Lasnon, Cathy Nganoa, Christophe Fruchart, Anne Claire Gac, Gandhi Damaj, Nicolas Aide
Background: When scoring 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) with the Deauville scale (DS), the quantification of tumor and reference organs limits the problem of optical misinterpretation. Compared to conventional reconstruction algorithms, point spread function (PSF) modeling significantly increases standardized uptake values (SUVs) in tumors but only moderately in the liver, which could affect the DS. We investigated whether the choice of the reconstruction algorithm affects the DS and whether discordances affect the capability of FDG PET to stratify lymphoma patients...
December 14, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Cheng-Cheng Liao, Yun-Ying Qin, Xiao-Hong Tan, Jia-Jie Hu, Qi Tang, Yan Rong, Hong Cen, Le-Qun Li
Objective: The objective of the study was to evaluate the prognostic value of positron emission tomography (PET)/computed tomography (CT) visual interpretation in patients with aggressive non-Hodgkin's lymphoma (NHL) using a meta-analysis and systematic review. Methods: Using the PubMed, Embase, and Web of Science databases, we performed a systematic review of the use of visual evaluation mid-chemotherapy to evaluate the prognosis of aggressive NHL in studies published up to May 2017...
2017: OncoTargets and Therapy
Lale Kostakoglu, Stéphane Chauvie
Although visual assessment using the Deauville criteria is strongly recommended by guidelines for treatment response monitoring in all FDG-avid lymphoma histologies, the high rate of false-positives and concerns about interobserver variability have motivated the development of quantitative tools to facilitate objective measurement of tumor response in both routine and clinical trial settings. Imaging studies using functional quantitative measures play a significant role in profiling oncologic processes. These quantitative metrics allow for objective end points in multicenter clinical trials...
January 2018: Seminars in Nuclear Medicine
Heiner Zimmermann, Timm Denecke, Martin H Dreyling, Christiane Franzius, Petra Reinke, Marion Subklewe, Holger Amthauer, Michael Kneba, Hanno Riess, Ralf U Trappe
BACKGROUND: Fluorine-18 fluorodeoxyglucose (18F-FDG) - positron-emission tomography (PET) is a recommended standard in the staging and response assessment of 18F-FDG-avid lymphoma. Posttransplant lymphoproliferative disorder (PTLD) can be detected by 18F-FDG-PET at diagnosis with high sensitivity and specificity. However, the role of response assessment by end of treatment (EOT)-PET has only been addressed in small case series. METHODS: We performed a retrospective, multi-center study of 37 patients with CD20-positive posttransplant lymphoproliferative disorder (PTLD) after solid organ transplantation (SOT) treated with uniform, up-to-date first-line protocols in the prospective German PTLD registry who had received EOT-18F-FDG-PET between 2006 and 2014...
November 17, 2017: Transplantation
Maoqing Jiang, Ping Chen, Xinzhong Ruan, Weiling Xu, Tianfu Li, Liyun Wu, Wenlan Zhou, Hubing Wu, Quanshi Wang
OBJECTIVE: In this study, we investigated the prognostic role of interim fluorine-18-fluorodeoxyglucose PET/computed tomography (I-PET/CT) and BCL2 in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab-containing chemotherapy. MATERIALS AND METHODS: A total of 106 patients with newly diagnosed DLBCL underwent PET/CT scans at baseline and a subsequent I-PET/CT after the fourth cycle of chemotherapy. I-PET/CT was analyzed using the Deauville five-point score...
February 2018: Nuclear Medicine Communications
Lisa Giulino-Roth, Tara O'Donohue, Zhengming Chen, Nancy L Bartlett, Ann LaCasce, William Martin-Doyle, Matthew J Barth, Kimberly Davies, Kristie A Blum, Beth Christian, Carla Casulo, Sonali M Smith, James Godfrey, Amanda Termuhlen, Matthew J Oberley, Sarah Alexander, Sheila Weitzman, Burton Appel, Benjamin Mizukawa, Jakub Svoboda, Zeinab Afify, Melinda Pauly, Hema Dave, Rebecca Gardner, Deborah M Stephens, William A Zeitler, Christopher Forlenza, Jennifer Levine, Michael E Williams, Jody L Sima, Catherine M Bollard, John P Leonard
Treatment with dose-adjusted EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone) chemotherapy and rituximab (DA-EPOCH-R) has become the standard of care for primary mediastinal B-cell lymphoma (PMBCL) at many institutions despite limited data in the multi-centre setting. We report a large, multi-centre retrospective analysis of children and adults with PMBCL treated with DA-EPOCH-R to characterize outcomes and evaluate prognostic factors. We assessed 156 patients with PMBCL treated with DA-EPOCH-R across 24 academic centres, including 38 children and 118 adults...
December 2017: British Journal of Haematology
Lucia Baratto, Guido A Davidzon, Mateen Moghbel, Negin Hatami, Andrei Iagaru, Erik S Mittra
OBJECTIVE: To evaluate the predictive value of interim PET (iPET) in diffuse large B-cell lymphoma (DLBCL) using 5 different imaging interpretation criteria: Deauville 5-point scale criteria, International Harmonization Project (IHP) criteria, Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, European Organization for Research and Treatment of Cancer, and PET Response Criteria in Solid Tumors (PERCIST) 1.0. METHODS: We retrospectively reviewed records from 38 patients with DLBCL who underwent baseline and iPET at our institution...
January 2018: Clinical Nuclear Medicine
J M Zaucha, B Malkowski, S Chauvie, E Subocz, J Tajer, W Kulikowski, A Fijolek-Warszewska, A Biggi, F Fallanca, M Kobylecka, M Dziuk, D Woszczyk, J Rybka, R Kroll-Balcerzak, F Bergesio, A Romanowicz, A Chamier-Cieminska, P Kurczab, A Giza, K Lesniewski-Kmak, R Zaucha, D Swietlik, T Wróbel, W Knopinska-Posluszny, J Walewski, A Gallamini
Background: Interim PET after two ABVD cycles (iPET2) predicts treatment outcome in classical Hodgkin's lymphoma. To test whether an earlier assessment of chemosensitivity would improve the prediction accuracy, we launched a prospective, multicenter observational study aimed at assessing the predictive value of iPET after one ABVD (iPET1) and the kinetics of response assessed by sequential PET scanning. Patients and methods: Consecutive patients with newly diagnosed classical Hodgkin's lymphoma underwent interim PET scan after one ABVD course (iPET1)...
December 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Vít Procházka, Rakhee S Gawande, Zuzan Cayci, Jerry W Froelich, Qing Cao, Chris Wilke, Kathryn Dusenbery, Daniel J Weisdorf, Veronika Bachanova
Autologous hematopoietic cell transplantation (AHCT) is curative for 60% of patients with relapsed or refractory Hodgkin lymphoma (R/R HL). A more precise assessment of the depth of remission before AHCT may help to identify patients likely to benefit from AHCT. We aimed to determine whether positron emission tomography (PET)-based quantitative parameters of total metabolic tumor volume (TMTV), total lesion glycolysis (TLG), and maximal standardized uptake volume (SUVmax ) measured before AHCT predict progression-free survival (PFS) after transplant...
January 2018: Biology of Blood and Marrow Transplantation
Sophia C Kamran, Heather A Jacene, Yu-Hui Chen, Peter M Mauch, Andrea K Ng
Our purpose was to assess outcome of patients with early-stage, favorable (per GHSG criteria) Hodgkin Lymphoma (HL) staged with FDG-PET/CT and treated with two cycles of adriamycin, bleomycin, vincristine, and dacarbazine (ABVD) followed by PET/CT assessment and involved-site radiotherapy (ISRT) to 20 Gy. Records of 23 patients who met eligibility criteria, treated between 2008 and 2016, were reviewed. PET response after two cycles of ABVD was independently assessed by a nuclear medicine physician. After two cycles of ABVD, 91...
September 22, 2017: Leukemia & Lymphoma
Alison J Moskowitz, Heiko Schöder, Somali Gavane, Katie L Thoren, Martin Fleisher, Joachim Yahalom, Susan J McCall, Briana R Cadzin, Stephanie Y Fox, John Gerecitano, Ravinder Grewal, Paul A Hamlin, Steven M Horwitz, Anita Kumar, Matthew Matasar, Andy Ni, Ariela Noy, M Lia Palomba, Miguel-Angel Perales, Carol S Portlock, Craig Sauter, David Straus, Anas Younes, Andrew D Zelenetz, Craig H Moskowitz
Identification of prognostic factors for patients with relapsed/refractory Hodgkin lymphoma (HL) is essential for optimizing therapy with risk-adapted approaches. In our phase 2 study of positron emission tomography (PET)-adapted salvage therapy with brentuximab vedotin (BV) and augmented ifosfamide, carboplatin, and etoposide (augICE), we assessed clinical factors, quantitative PET assessments, and cytokine and chemokine values. Transplant-eligible patients with relapsed/refractory HL received 2 (cohort 1) or 3 (cohort 2) cycles of weekly BV; PET-negative patients (Deauville score ≤2) proceeded to autologous stem cell transplantation (ASCT) whereas PET-positive patients received augICE before ASCT...
November 16, 2017: Blood
Anne-Segolene Cottereau, Tarec C El-Galaly, Stéphanie Becker, Florence Broussais, Lars Jelstrup Peterson, Christophe Bonnet, John O Prior, Herve Tilly, Martin Hutchings, Olivier Casasnovas, Michel A Meignan
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas with poor outcomes with current therapy. We investigated if response assessed with Positron Emission Tomography/computed tomography (PET/CT) combined with baseline total metabolic tumor volume (TMTV) could detect early relapse/refractory patients. Methods: 140 patients with nodal PTCL who underwent baseline PET/CT were selected from 7 European centers. 43 had interim PET (iPET) performed after two cycles (iPET2), 95 after 3 or 4 cycles (iPET3/4) and 96 had end of treatment PET (eotPET)...
September 1, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Chong Jiang, Jie Liu, Li Li, Russell O Kosik, Minggang Su, Liqun Zou, Rong Tian
PURPOSE: The aim of this study was to assess the prognostic capacity of three methods of fluorine-18-fluorodeoxyglucose (F-FDG) PET/CT analysis carried out after therapy in patients with extranodal natural killer/T-cell lymphoma (ENKTL). The three methods of PET/CT analysis included the International Harmonization Project (IHP) criteria, the Deauville five-point scale (5-PS), and standardized uptake value (SUV)-based assessment. PATIENTS AND METHODS: Fifty-nine patients diagnosed with ENKTL were enrolled...
November 2017: Nuclear Medicine Communications
Allison Winter, Lisa Rybicki, Shetal N Shah, Deepa Jagadeesh, Aaron T Gerds, Betty K Hamilton, Hien Liu, Robert Dean, Ronald Sobecks, Brad Pohlman, Mitchell Smith, Matt Kalaycio, Brian J Bolwell, Navneet S Majhail, Brian T Hill
Pre-transplant PET/CT may be prognostic in diffuse large B-cell lymphoma (DLBCL) patients undergoing autologous stem cell transplantation (ASCT). We reviewed relapsed and pre-transplant PET/CT scans of 32 patients with DLBCL treated with ASCT to determine the Deauville score and the maximum standardized uptake value (SUVmax). Patients with a Deauville score of 4 had a significantly inferior prognosis. The 3-year progression-free survival (PFS) for patients with Deauville 1-3 score was 64%, compared to 0% for Deauville 4, while the 3-year overall survival (OS) was 84% and 25%, respectively (p < ...
August 30, 2017: Leukemia & Lymphoma
Michel Meignan, Anne-Ségolène Cottereau
No abstract text is available yet for this article.
August 30, 2017: Leukemia & Lymphoma
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"